By Fineline Cube China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with compatriot firm Shenzhen Alpha Molecular Technology Co., Ltd to enhance the artificial intelligence (AI)-empowered research and development of obesity drugs. The collaboration aims to leverage the combined strengths of both companies in the field of drug discovery and development. No financial details were disclosed.
Partnership Details
The partnership will integrate Salubris’s capabilities in drug discovery, development, and clinical transformation with Alpha’s expertise in biocomputing, AI, and original biotechnologies. The goal is to develop new therapies targeting obesity. Alpha Molecular Technology is known for its innovative biotechnologies, including the world’s first optical biochip for testing G protein coupled receptor proteins, the world’s first biochip for testing cell electrophysiology, and the world’s first biochip for tracking single molecule cells.
Future Outlook
With this collaboration, Salubris and Alpha Molecular Technology are poised to advance the development of novel obesity treatments, leveraging AI and biotechnology to address the growing need for effective therapies in this area.-Fineline Info & Tech